VIVUS Announces Date of Third Quarter 2012 Financial Results and Conference Call

VIVUS Announces Date of Third Quarter 2012 Financial Results and Conference

MOUNTAIN VIEW, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS) today announced that it will report financial results for the
third quarter ended September 30, 2012 before the NASDAQ Market opens on
Tuesday, November 6, 2012. The company will conduct a conference call and an
audio webcast at 8:45am ET on the same day.

The company will conduct a conference call and an audio webcast at 8:45am ET
on the same day.

Date:                                 November 6, 2012
Time:                                 8:45 AM ET
Listen via Internet:       
Schedule this webcast into MS-Outlook calendar (click open when prompted):
Toll-free:                           877-359-2916
International:                       224-357-2386
A webcast replay will be available on the VIVUS web site for 30 days.


VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health for U.S., Europe and other world markets.
Qsymia, which the company intends to market outside of the U.S. under the name
Qsiva™, is also in phase 2 clinical development for the treatment of type 2
diabetes and obstructive sleep apnea.For more information about the company,
please visit

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, our lack of commercial experience
with Qsymia in the U.S.; the timing of initiation and completion of the
clinical studies required as part of the approval of Qsymia by the United
States Food and Drug Administration, or FDA; the response from the FDA to the
data that VIVUS will submit relating to post-approval clinical studies; the
impact of the indicated uses and contraindications contained in the Qsymia
label and the REMS requirements; the impact of distribution of Qsymia through
a certified pharmacy network; that we may be required to provide further
analysis of previously submitted clinical trial data; ourappeal of the
negative opinion of the European Medicines Agency's, or EMA, Committee for
Medicinal Products for Human Use, or CHMP, for the Marketing Authorization
Application, or MAA, for Qsymia; our ability to successfully commercialize or
establish a marketing partnership for avanafil, which will be marketed in the
U.S. under the name STENDRA™, or our partner's ability to obtain and maintain
regulatory approval to manufacture and adequately supply avanafil to meet
demand; our history of losses and variable quarterly results; substantial
competition; risks related to the failure to protect our intellectual property
and litigation in which we may become involved; uncertainties of government or
third party payer reimbursement; our reliance on sole source suppliers; our
limited sales and marketing and manufacturing experience; our reliance on
third parties and our collaborative partners; our failure to continue to
develop innovative investigational drug candidates and drugs; risks related to
the failure to obtain FDA or foreign authority clearances or approvals and
noncompliance with FDA or foreign authority regulations; our ability to
demonstrate through clinical testing the safety and effectiveness of our
investigational drug candidates; the timing of initiation and completion of
clinical trials and submissions to foreign authorities; the volatility and
liquidity of the financial markets; our liquidity and capital resources; and
our expected future revenues, operations and expenditures. As with any
pharmaceutical in development, there are significant risks in the development,
the regulatory approval, and commercialization of new products. There are no
guarantees that the product will receive regulatory approval outside the
United States for any indication or prove to be commercially successful. VIVUS
does not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS' Form
10-K for the year ending December 31, 2011, and periodic reports filed with
the Securities and Exchange Commission.

         Timothy E. Morris
         Chief Financial Officer

         Investor Relations:
         The Trout Group
         Brian Korb
Press spacebar to pause and continue. Press esc to stop.